Amgen elects Robert Bradway to board
This article was originally published in Scrip
Amgen's former CFO, Robert Bradway, has been elected to serve on the company's board of directors. He served as Amgen's CFO from 2007-2010, having joined the company in 2006 as vice-president of operations strategy. Prior to Amgen he worked at Morgan Stanley as a managing director.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.